Welcome to our dedicated page for CATALYST PHARMACEUTICALS SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals Chief Legal Officer Brian Elsbernd reported the cancellation of his equity interests in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. On July 15, 2026, 242,501 common shares were disposed of at $31.50 per share, and all reported RSUs and stock options were cancelled and converted into cash rights using a $31.50 per share amount in the payout formulas. Following these transactions, the filing lists zero remaining holdings of the reported securities.
CATALYST PHARMACEUTICALS director Daniel J. Curran reported dispositions of equity awards to the issuer in connection with the consummation of a Merger. On 2026-07-15, 5,468 restricted stock units and stock options over 18,115 and 40,000 shares of common stock were cancelled. Each restricted stock unit represented a contingent right to receive one share, and each award was converted into a right to receive a cash payment based on a $31.50 per-share merger price, less the applicable option exercise prices. All reported options and RSUs vested in full at closing, and these derivative positions now show zero shares following the transactions.
Catalyst Pharmaceuticals director David S. Tierney reported the disposition of 383,314 shares of common stock at $31.50 per share to the issuer on July 15, 2026, in connection with the acquisition by Angelini Pharma S.p.A. All reported RSUs and fully vested stock options were cancelled at closing and converted into cash based on the $31.50 merger price, leaving no reported remaining holdings of these securities.
Steve Miller, chief operating and scientific officer of Catalyst Pharmaceuticals, reported the disposition to the issuer of 1,093,803 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).
On the same date, all reported restricted stock units (47,826; 16,534; 11,873 underlying shares) and multiple option grants (including 158,454 options at $22.77, 202,958 at $21.12 and 275,000 at $3.42) were canceled and converted into rights to receive cash based on a $31.50 reference price per share. Each option and RSU vested in full at consummation of the Merger, and reported holdings after these transactions were 0 shares and 0 derivative securities.
Catalyst Pharmaceuticals director Tamar Thompson reported the disposition of all reported equity positions in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. On 2026-07-15, 3,773 shares of common stock were surrendered at $31.50 per share, and multiple restricted stock unit and stock option awards covering specified shares were cancelled and converted into cash based on the $31.50 per-share merger price. Following these transactions, the reported holdings show 0 shares and 0 derivative awards remaining for the positions covered.
CATALYST PHARMACEUTICALS, INC. Chief HR Officer Gregg Russo disposed of equity in connection with the acquisition by Angelini Pharma S.p.A. at $31.50 per share. The report shows the return of 476 common shares plus multiple RSUs and stock options to the issuer for cash consideration. After these transactions, no holdings in the reported securities remain.
Patrick J. McEnany, chairman of Catalyst Pharmaceuticals, reported the disposition of 4,171,559 shares of common stock at $31.50 per share in connection with the acquisition of Catalyst by Angelini Pharma S.p.A., and this Form 4 shows 0 shares of common stock held directly afterward.
The reported restricted stock units and stock options covering additional shares were cancelled at merger closing and converted into rights to receive cash payments based on a $31.50 per-share value, with each award vesting in full at consummation.
CATALYST PHARMACEUTICALS, INC. director Donald A. Denkhaus reported disposing of 498,773 shares of common stock at $31.50 per share on July 15, 2026, in a disposition to the issuer completed in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).
On the same date, all reported restricted stock units and stock options, covering additional shares of common stock, were cancelled and converted into rights to receive cash payments based on the $31.50 per-share merger consideration, and his reported holdings in these securities fell to 0.
Catalyst Pharmaceuticals Chief Commercial Officer Jeffrey Del Carmen reported issuer dispositions on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. He disposed of 14,337 common shares at $31.5000 per share, and all reported restricted stock units and stock options vested in full, were canceled, and converted into rights to receive cash payments calculated using a $31.50 per-share merger price. Following these transactions, he reports no remaining Catalyst equity holdings, including common stock, RSUs, or stock options.